Literature DB >> 20405

Complement levels in pneumococcal pneumonia.

J D Coonrod, B Rylko-Bauer.   

Abstract

Levels of complement proteins and functional activity of the alternate complement pathway were assessed in 39 patients with pneumococcal pneumonia. Mean levels of C3 and properdin and the functional activity of the alternate pathway in acute sera were significantly (P less than 0.05) below normal, whereas levels of components of the early classical pathway were normal. Although levels of factor B were in the normal range, they correlated significantly with C3 levels; there was no significant relation between C3 levels and C4 or C1q levels. The 19 patients iwth pneumococcal pneumonia and bacteremia had significantly lower mean values of properdin and factor B than the 20 patients without bacteremia, suggesting a more severe depression of the alternate complement pathway with bacteremia. During convalescence, complement levels were normal or elevated in most of the patients, but mean levels of properdin remained significantly below normal in bacteremic patients. Functional activity of the alternate pathway also remained below normal. These results indicate that there is a selective depression of the alternate pathway in patients with pneumococcal pneumonia, and they are consistent with the concept that the alternate pathway has an important role in host defenses in pneumococcal infection.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 20405      PMCID: PMC421186          DOI: 10.1128/iai.18.1.14-22.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Pneumococcal type-associated variability in alternate complement pathway activation.

Authors:  D P Fine
Journal:  Infect Immun       Date:  1975-10       Impact factor: 3.441

2.  Pneumococcal pneumonia treated with antibiotics; the prognostic significance of certain clinical findings.

Authors:  T E VAN METRE
Journal:  N Engl J Med       Date:  1954-12-23       Impact factor: 91.245

3.  IMMUNOLOGICAL STUDIES ON PATIENTS WITH PNEUMOCOCCIC PNEUMONIA TREATED WITH SULFAPYRIDINE.

Authors:  M Finland; W C Spring; F C Lowell
Journal:  J Clin Invest       Date:  1940-01       Impact factor: 14.808

4.  The role of the capsular polysaccharide in the activation of the alternative pathway by the pneumococcus.

Authors:  J A Winkelstein; J A Bocchini; G Schiffman
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

5.  Antigenic determinants of human beta-1c and beta-1g-globulins.

Authors:  C West; N C Davis; J Forristal; J Herbst; R Spitzer
Journal:  J Immunol       Date:  1966-04       Impact factor: 5.422

6.  Reduced serum beta 1c/1a globulin levels in extrarenal disease.

Authors:  M H Grieco; J D Capra; H Paderon
Journal:  Am J Med       Date:  1971-09       Impact factor: 4.965

7.  An abnormality of the alternate pathway of complement activation in sickle-cell disease.

Authors:  R B Johnston; S L Newman; A G Struth
Journal:  N Engl J Med       Date:  1973-04-19       Impact factor: 91.245

8.  Pneumococcal pneumonia: capsular polysaccharide antigenemia and antibody responses.

Authors:  J D Coonrod; D P Drennan
Journal:  Ann Intern Med       Date:  1976-03       Impact factor: 25.391

9.  Complement system in pneumococcal infections.

Authors:  W P Reed; M S Davidson; R C Williams
Journal:  Infect Immun       Date:  1976-04       Impact factor: 3.441

10.  On the nature of bacteremia in experimental pneumococcal pneumonia in the dog. I. Relationship of natural pneumococcidal-promoting activity of the serum to blood invasion.

Authors:  O H ROBERTSON; M HAMBURGER; L A GREGG
Journal:  J Exp Med       Date:  1953-02-01       Impact factor: 14.307

View more
  13 in total

1.  Interaction of pneumococcal antigens with complement in rats.

Authors:  J D Coonrod; S Jenkins
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

2.  Activation of human complement by the pneumococcal toxin pneumolysin.

Authors:  J C Paton; B Rowan-Kelly; A Ferrante
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

Review 3.  Complement system in lung disease.

Authors:  Pankita H Pandya; David S Wilkes
Journal:  Am J Respir Cell Mol Biol       Date:  2014-10       Impact factor: 6.914

4.  Alterations in serum opsonic activity and complement levels in pneumococcal disease.

Authors:  G S Giebink; T H Dee; Y Kim; P G Quie
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

5.  Complement activation by Coccidioides immitis: in vitro and clinical studies.

Authors:  J N Galgiani; P Yam; L D Petz; P L Williams; D A Stevens
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

6.  Effect of intravenously injected killed pneumococci on leukocytes, complement, and phagocytosis in rabbits.

Authors:  W P Reed; P Jaffee; E L Albright; R C Williams
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

7.  Complement activation in pneumonia.

Authors:  U Nydegger; J J Farquet; R Zubler; P H Lambert; P A Miescher
Journal:  Med Microbiol Immunol       Date:  1979       Impact factor: 3.402

8.  Relationships between alternative complement pathway activation, C-reactive protein, and pneumococcal infection.

Authors:  R A Rabinovitch; S M Koethe; J H Kalbfleisch; L C Preheim; M W Rytel
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

9.  Serum opsonic deficiency produced by Streptococcus pneumoniae and by capsular polysaccharide antigens.

Authors:  G S Giebink; J V Grebner; Y Kim; P G Quie
Journal:  Yale J Biol Med       Date:  1978 Sep-Oct

10.  Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: A post-hoc analysis.

Authors:  Simone M C Spoorenberg; Stefan M T Vestjens; G P Voorn; Coline H M van Moorsel; Bob Meek; Pieter Zanen; Ger T Rijkers; Willem Jan W Bos; Jan C Grutters
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.